Clinical Trials Logo

Superficial Bladder Cancer clinical trials

View clinical trials related to Superficial Bladder Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05084586 Recruiting - Bladder Cancer Clinical Trials

Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation

Start date: October 1, 2019
Phase: N/A
Study type: Interventional

In this study, the local and systemic side effects, tumor recurrens and progression rates of single or continuous epirubicin instillation during the early postoperative period were investigated in low and intermediate risk non-muscle-invasive bladder cancer.

NCT ID: NCT04752722 Recruiting - Clinical trials for Superficial Bladder Cancer

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Start date: April 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.

NCT ID: NCT03379909 Recruiting - Bladder Cancer Clinical Trials

Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer

TROJAN
Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

A multi-center, open-label, phase II clinical study of metformin in up to evaluable 49 patients with low-grade NMIBC with the aim to determine the overall response to administration of oral metformin for 3 months in a index papillary NMIBC tumour.

NCT ID: NCT03121768 Recruiting - Bladder Cancer Clinical Trials

A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: May 15, 2017
Phase: N/A
Study type: Observational

A prospective observational study to re-establish a new prognostic model for predicting the outcome in patients with non-muscle invasive bladder cancer (NMIBC) using the current recommendation regimen for intermediate and high risk groups and including all potential and highly prognostic factors.

NCT ID: NCT02106572 Recruiting - Clinical trials for Superficial Bladder Cancer

Therapeutic Instillation of Mistletoe

TIM
Start date: April 2015
Phase: Phase 3
Study type: Interventional

The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM® 900, in particular, to compare the toxicity of the two treatments. Another secondary objective is the treatment efficacy as measured by calculated prognosis for recurrence and progression after 1 year, the tumor grading in case of a recurrence and by measurement of Quality of Life.